Lercanidipine Zydus

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Zydus, is a calcium channel blocker presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Lercanidipine Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance. The company adheres to Good Distribution Practice standards and provides reliable logistics for global health care providers. Our network enables timely delivery to diverse markets while maintaining product integrity.

Lercanidipine is a calcium channel blocker used in the management of high‑blood‑pressure disorders. - Essential hypertension: Lowers systolic and diastolic blood pressure, helping patients achieve target levels and reduce cardiovascular risk. - Isolated systolic hypertension: Provides effective reduction of systolic pressure in older adults where pulse pressure is predominant. - Secondary hypertension due to renal disease: Assists in controlling blood pressure when other antihypertensives are insufficient. - Hypertension in patients with metabolic syndrome: Contributes to blood pressure control without adversely affecting glucose metabolism.

Lercanidipine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate headache reported in clinical use. - Flushing: transient facial flushing due to vasodilation. - Peripheral edema: swelling of ankles or lower limbs. - Dizziness: sensation of light‑headedness, especially after standing. - Tachycardia: increased heart rate occasionally observed. - Nausea: occasional nausea or stomach discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals. - Liver enzyme elevation: abnormal hepatic transaminases requiring monitoring. - Angioedema: swelling of face, lips or throat that may compromise airway.

When prescribing lercanidipine, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: monitor blood pressure and renal function, dose adjustment may be required. - Hepatic impairment: use with caution; reduced metabolism can increase plasma concentrations. - Concomitant CYP3A4 inhibitors: avoid or adjust dose as drug levels may rise. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Elderly patients: start at low dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Lercanidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase lercanidipine plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may substantially reduce therapeutic effect. - Other antihypertensives (e.g., ACE inhibitors, diuretics): risk of additive hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: monitor heart rate and blood pressure for excessive bradycardia. - Diuretics: watch for electrolyte disturbances and enhanced blood pressure lowering. - Grapefruit juice: may increase drug exposure; advise patients to limit consumption.